Pluristyx provides the expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics to treat serious human diseases by providing unique products, expert consulting, and contract services

Supporting the commercialization of revolutionary new therapies


Contract process development and manufacturing of cell based products

Ready-to-Differentiate™ human Pluripotent Stem Cells and induced Pluripotent Stem Cells

Ready-to-Use™ differentiated PSC

Recent News


Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program

SEATTLE--(BUSINESS WIRE)-- Pluristyx, Inc., a leading chemistry, manufacturing, and controls (CMC), consulting, process development, and tools provider for cell and gene therapy companies, today announced it will be supporting a collaboration between Kiadis Pharma (Kiadis), and the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program working on Kiadis’ COVID-19 research and development program, Kiadis’ Natural Killer cells, (K-NK-ID101) as a universal countermeasure to fight COVID-19 and future pandemics.


Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments | Business Wire


AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

ALAMEDA, Calif. & SEATTLE--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeX’s research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs.


Pluristyx Featured in Labroots webinar

Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB.